In the last trading session, 1.39 million Allarity Therapeutics Inc (NASDAQ:ALLR) shares changed hands as the company’s beta touched 0.25. With the company’s per share price at $0.70 changed hands at -$0.12 or -14.03% during last session, the market valuation stood at $3.13M. ALLR’s last price was a discount, traded about -37614.29% off its 52-week high of $264.00. The share price had its 52-week low at $0.76, which suggests the last value was -8.57% down since then.

Analysts gave the Allarity Therapeutics Inc (ALLR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ALLR as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Allarity Therapeutics Inc’s EPS for the current quarter is expected to be 0.

Allarity Therapeutics Inc (NASDAQ:ALLR) trade information

Instantly ALLR was in red as seen at the end of in last trading. With action -29.49%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -39.74%, with the 5-day performance at -29.49% in the red. However, in the 30-day time frame, Allarity Therapeutics Inc (NASDAQ:ALLR) is -48.16% down.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 57.56%.

ALLR Dividends

Allarity Therapeutics Inc is expected to release its next quarterly earnings report in March.

Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Extended Market Index Fund and Fidelity Series Total Market Index Fund . With 7.19 shares estimated at $5070.0 under it, the former controlled 0.16% of total outstanding shares. On the other hand, Fidelity Series Total Market Index Fund held about 0.04% of the shares, roughly 1.93 shares worth around $1363.0.